Final 36-Month Outcomes from the Multicenter DynamX Study Evaluating a Novel Thin-Strut Novolimus-Eluting Coronary Bioadaptor System and Supporting Preclinical Data
Verheye S, Vrolix M, Montorfano M, Giannini F, Bedogni F, Dubois C, De Bruyne B, Costa R, Chamié D, Costa J, Abizaid A, Colombo A. Final 36-Month Outcomes from the Multicenter DynamX Study Evaluating a Novel Thin-Strut Novolimus-Eluting Coronary Bioadaptor System and Supporting Preclinical Data. Reviews In Cardiovascular Medicine 2023, 24: 221. PMID: 39076703, PMCID: PMC11266769, DOI: 10.31083/j.rcm2408221.Peer-Reviewed Original ResearchDrug-eluting stentsOptical coherence tomographyTarget lesion revascularizationExpression of contractile genesPreclinical studiesLesion revascularizationGene expression profilesClinically-driven target lesion revascularizationIntention-to-treat populationContractile genesCoronary arteryIncreased expressionLong-term adverse outcomesClinical follow-upLate lumen enlargementCell gene expression profilesRestoring vessel functionTarget vessel revascularizationTarget lesion failureReal-time polymerase chain reactionPreclinical dataExpression profilesClinical outcomesLumen enlargementCardiac death
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply